Christopher M. Smith - 23 Feb 2025 Form 4 Insider Report for NEOGENOMICS INC (NEO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
25 Feb 2025, 16:37:34 UTC
Prior SEC filing
03 Feb 2025
Next SEC filing
06 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Ali Olivo, Attorney-in-Fact

Key filing fact

Christopher M. Smith filed Form 4 for NEOGENOMICS INC (NEO) on 25 Feb 2025.

Key facts

  • This page summarizes Christopher M. Smith's Form 4 filing for NEOGENOMICS INC (NEO).
  • 3 reported transactions and 7 derivative rows are listed below.
  • Accepted by SEC: 25 Feb 2025, 16:37.

Change

  • Previous filing in this sequence was filed on 03 Feb 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NEO transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+57,413
Change %
+9.6%
Price
$0.000000
Shares after
655,652
Date
23 Feb 2025
Ownership
Direct
Footnotes
F1
NEO transaction

Common Stock

Tax liability

Transaction value
$0
Shares
-14,067
Change %
-2.1%
Price
$0.000000
Shares after
641,585
Date
23 Feb 2025
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NEO transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-57,413
Change %
-33%
Price
$0.000000
Shares after
114,826
Date
23 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
57,413
Exercise price
$0.000000
Footnotes
F3, F4
NEO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
694,444
Date
23 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
694,444
Exercise price
$12.62
Footnotes
F5
NEO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
269,841
Date
23 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
269,841
Exercise price
$19.65
Footnotes
F6
NEO holding Derivative

Restricted Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
96,127
Date
23 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
96,127
Exercise price
$0.000000
Footnotes
F4, F7
NEO holding Derivative

Performance Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
144,190
Date
23 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
144,190
Exercise price
$0.000000
Footnotes
F4, F8
NEO holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
287,940
Date
23 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
287,940
Exercise price
$16.45
Footnotes
F9
NEO holding Derivative

Performance Stock Unit

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
172,240
Date
23 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
172,240
Exercise price
$0.000000
Footnotes
F4, F10
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.

Footnote F2

Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.

Footnote F3

On February 23, 2024, Mr. Smith was granted 172,239 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.

Footnote F4

Once vested, the shares of common stock are not subject to expiration.

Footnote F5

On August 15, 2022, Mr. Smith was granted 694,444 stock options. These options vest ratably over the first four anniversary dates of the grant date.

Footnote F6

On May 11, 2023, Mr. Smith was granted 269,841 stock options. These options vest ratably over the first three anniversary dates of the grant date.

Footnote F7

On May 11, 2023, Mr. Smith was granted 144,190 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.

Footnote F8

On May 11, 2023, Mr. Smith was granted 144,190 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 216,285. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.

Footnote F9

On February 23, 2024, Mr. Smith was granted 287,940 stock options. These options vest ratably over the first three anniversary dates of the grant date.

Footnote F10

On February 23, 2024, Mr. Smith was granted 172,240 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 258,360. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .